MDY buys investments from 3i for GBP3M
UK life science investor MDY Healthcare has acquired stakes in Scottish drugmaker ProStrakan and Swiss firm Santhera Pharmaceuticals Holding AG from the 3i Group for a total consideration of GBP3.0 million ($4.3 million).
MDY has agreed to buy over 2.4 million ordinary shares in ProStrakan, at a price of 61.5 pence each, and over 49,362 common shares in Santhera for 49.65 francs each. The prices paid are the respective bid prices per share at the close of business on March 19. These stakes represent 1.21% of ProStrakan and 1.40% of Santhera.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze